New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

The findings could lead to genetic tests that predict the likelihood of disease recurrence in breast cancer patients and ...

Genomic tests give us a clearer picture of how aggressive prostate cancer might be. While these tests show promise, we need more well-designed studies to see exactly how they can improve treatment ...

For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs ... after GPS testing were seen. "Although GC tests do not consistently influence risk classification ...

A systematic review concluded that while genomic classifier (GC) tests could affect risk classifications or treatment choices for patients with localized prostate cancer (PCa), more research is ...

A systematic review found that genomic classifier tests can influence risk assessments and treatment decisions among patients with localized prostate cancer but studies evaluating these tests vary ...

a novel biopsy test that provides improved estimation of a patient's risk of prostate cancer recurrence and allows for optimal treatment selection. Currently, the U.S. is the major market for ...

According to the American Cancer Society ... validation of its biopsy test which provides an “improved estimation” of a patient’s risk of prostate cancer recurrence. Now, on the heels ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

Opens in a new tab or window Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer ...

TAMPA, Fla. (Jan. 24, 2025) — A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris ...